PURPOSE: Adult patients with relapsed high-grade glioma are a very heterogenous group with, however, an invariably dismal prognosis. We stratified patients with relapsed high-grade glioma treated with re-operation and postoperative dendritic cell (DC) vaccination according to a simple recursive partitioning analysis (RPA) model to predict outcome. PATIENTS AND METHODS: Based on age, pathology, Karnofsky performance score, and mental status, 117 adult patients with relapsed malignant glioma, undergoing re-operation, and postoperative adjuvant dendritic cell (DC) vaccination were stratified into 4 classes. Kaplan-Meier survival estimates were generated for each class of this HGG-IMMUNO RPA model. Extent of resection was documented but not included in the prognostic model. RESULTS: Kaplan-Meier overall survival estimates revealed significant (p < 0.0001) differences among the 4 HGG-IMMUNO RPA classes. Long-term survivors, surviving more than 24 months after the re-operation and vaccination, are seen in 54.5, 26.7, 11.5, and 0 % for the classes I, II, III, and IV respectively. CONCLUSION: This HGG-IMMUNO RPA classification is able to predict overall survival in a large group of adult patients with a relapsed malignant glioma, treated with re-operation and postoperative adjuvant DC vaccination in the HGG-IMMUNO-2003 cohort comparison trial. The model appears useful for prognostic patient counseling for patients participating in DC vaccination trials. A substantial number of long-term survivors after relapse are seen in class I to III, but not in class IV patients.
PURPOSE: Adult patients with relapsed high-grade glioma are a very heterogenous group with, however, an invariably dismal prognosis. We stratified patients with relapsed high-grade glioma treated with re-operation and postoperative dendritic cell (DC) vaccination according to a simple recursive partitioning analysis (RPA) model to predict outcome. PATIENTS AND METHODS: Based on age, pathology, Karnofsky performance score, and mental status, 117 adult patients with relapsed malignant glioma, undergoing re-operation, and postoperative adjuvant dendritic cell (DC) vaccination were stratified into 4 classes. Kaplan-Meier survival estimates were generated for each class of this HGG-IMMUNO RPA model. Extent of resection was documented but not included in the prognostic model. RESULTS: Kaplan-Meier overall survival estimates revealed significant (p < 0.0001) differences among the 4 HGG-IMMUNO RPA classes. Long-term survivors, surviving more than 24 months after the re-operation and vaccination, are seen in 54.5, 26.7, 11.5, and 0 % for the classes I, II, III, and IV respectively. CONCLUSION: This HGG-IMMUNO RPA classification is able to predict overall survival in a large group of adult patients with a relapsed malignant glioma, treated with re-operation and postoperative adjuvant DC vaccination in the HGG-IMMUNO-2003 cohort comparison trial. The model appears useful for prognostic patient counseling for patients participating in DC vaccination trials. A substantial number of long-term survivors after relapse are seen in class I to III, but not in class IV patients.
Authors: Martin K Hunn; Evelyn Bauer; Catherine E Wood; Olivier Gasser; Marina Dzhelali; Lindsay R Ancelet; Brigitta Mester; Katrina J Sharples; Michael P Findlay; David A Hamilton; Ian F Hermans Journal: J Neurooncol Date: 2014-10-31 Impact factor: 4.130
Authors: Klaus Müller; Guido Henke; Sophie Pietschmann; Stefaan van Gool; Steven De Vleeschouwer; André O von Bueren; Inge Compter; Carsten Friedrich; Christiane Matuschek; Gunther Klautke; Rolf-Dieter Kortmann; Thomas Hundsberger; Brigitta G Baumert Journal: J Neurooncol Date: 2015-06-13 Impact factor: 4.130
Authors: David A Reardon; Kai W Wucherpfennig; Gordon Freeman; Catherine J Wu; E Antonio Chiocca; Patrick Y Wen; William T Curry; Duane A Mitchell; Peter E Fecci; John H Sampson; Glenn Dranoff Journal: Expert Rev Vaccines Date: 2013-06 Impact factor: 5.217
Authors: David A Reardon; Gordon Freeman; Catherine Wu; E Antonio Chiocca; Kai W Wucherpfennig; Patrick Y Wen; Edward F Fritsch; William T Curry; John H Sampson; Glenn Dranoff Journal: Neuro Oncol Date: 2014-09-04 Impact factor: 12.300
Authors: Lien Vandenberk; Abhishek D Garg; Tina Verschuere; Carolien Koks; Jochen Belmans; Monique Beullens; Patrizia Agostinis; Steven De Vleeschouwer; Stefaan W Van Gool Journal: Oncoimmunology Date: 2015-09-11 Impact factor: 8.110